Pharmacogenetics of thiopurine therapy in paediatric IBD patients

Alimentary Pharmacology and Therapeutics

Volumn 23, Issue 8, 2006, Pages 1137-1141

  De Ridder, L ^a   Van Dieren, J M ^b   Van Deventer, H J H ^c   Stokkers, P C F ^c   Van Der Woude, J C J ^b   Van Vuuren, A J ^b   Benninga, M A ^a   Escher, J C ^b   Hommes, D W ^c  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AZATHIOPRINE; INORGANIC PYROPHOSPHATASE; INOSINE TRIPHOSPHATE PYROPHOSPHATASE; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHILD; CONTROLLED STUDY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; GENE FREQUENCY; GENE FUNCTION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; HYPERAMYLASEMIA; IRRITABLE COLON; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; NAUSEA; PANCREATITIS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; WILD TYPE;

ADOLESCENT; AZATHIOPRINE; CHI-SQUARE DISTRIBUTION; CHILD; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; LEUKOPENIA; MALE; METHYLTRANSFERASES; PANCREATITIS; POLYMORPHISM, GENETIC; PYROPHOSPHATASES;

EID: 33646879828     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02853.x     Document Type: Article

References (20)

1. Pearson DC May GR Fick G, et al. Azathioprine for maintenance of remission in Crohn's disease (Cochrane Review). In : The Cochrane Library, Issue 3. Chichester, UK : John Wiley and Sons, Ltd, 2003
2. Markowitz J Grancher K Kohn N Lesser M Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000 119 : 895 902.
3. Fuentes D Torrente F Keady S, et al. High-dose azathioprine in children with inflammatory bowel disease. Aliment Pharmacol Ther 2003 17 : 913 21.
4. Cuffari C Hunt S Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001 48 : 642 6.
5. Hamdan-Khalil R Gala J-L Allorge D, et al. Identification and functional analysis of two rare allelic variants of the thiopurine S-methyltransferase gene, TPMT*16 and TPMT*19. Biochem Pharmacol 2005 69 : 525 9.
6. Otterness D Szumlanski C Lennard L, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997 62 : 60 73.
7. Gearry RB Barclay ML Burt MJ, et al. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003 18 : 395 400.
8. Dubinsky MC Lamothe S Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000 118 : 705 13.
9. Marinaki AM Ansari A Duley JA, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004 14 : 181 7.
10. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989 170 : 2 6.
11. Barabino A Torrente F Ventura A Cucchiara S Castro M Barbera C. Azathioprine in paediatric inflammatory bowel diseases: an Italian multicentre survey. Aliment Pharmacol Ther 2002 16 : 1125 30.
12. Pearson DC May GR Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995 123 : 132 42.
13. Present DH Meltzer SJ Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989 111 : 641 9.
14. Connell WR Kamm MA Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993 34 : 1081 5.
15. Korelitz BI Zlatanic J Goel F, et al. Allergic reactions to 6-mercaptopurine during treatment of inflammatory bowel disease. J Clin Gastroenterol 1999 28 : 341 4.
16. Weinshilboum RM. Thiopurine pharmacogenetics. Clinical and molecular studies of thiopurine methyltransferase. Drug metab Disp 2001 29 : 601 5.
17. Reuther LO Sonne J Larsen N Dahlerup JF Thomsen OO Schiegelow K. Thiopurine methyl transferase activity in patients with Crohn's disease. Aliment Pharmacol Ther 2003 17 : 65 67.
18. Kader HA Wenner WJ Telega GW Maller ES Baldassano RN. Normal Thiopurine methyltransferase levels do not eliminate mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease. J Clin Gastroenterol 2000 30 : 409 13.
19. Gearry RB Roberts RL Barclay ML Kennedy MA. Lack of association between the ITPAC>A polymorphism and adverse effects from azathioprine. Pharmacogenetics 2004 14 : 779 81.
20. Weinshilboum RM Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980 32 : 651 62.